Scott Irwin is a Psychiatry physician affiliated with Sinai Health System. OpenAlex indexes 124 publications with 6,762 citations (h-index 34); ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4311 Third Ave
San Diego, CA 921031407
Telephone
619-688-1600Registry record last updated 9 Aug 2010.
Clinical trials
- Living Well Program: Impact on Healthcare Costs and Clinical Outcomes in Breast Cancer Care
Sponsor: Scott A. Irwin, MD, PhD
- Feasibility Study of Oral Ketamine Versus Placebo for the Treatment of Anxiety in Patients With Pancreatic Cancer
Sponsor: Cedars-Sinai Medical Center
- Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
Sponsor: Cedars-Sinai Medical Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
100%Benzodiazepine48.4%Clonazepam41%Lorazepam36%Alprazolam13%Diazepam11%Part D<11 patientsSNRI18.1%Venlafaxine Hcl Er72%Duloxetine Hcl28%Part D<11 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 2010–2025 per NIH RePORTER. The latest:
- Randomized Controlled Trial of Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
Cedars-Sinai Medical Center
FY2025$591,720R01CA252211 - Randomized Controlled Trial of Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
Cedars-Sinai Medical Center
FY2024$601,042R01CA252211 - Randomized Controlled Trial of Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
Cedars-Sinai Medical Center
FY2023$623,293R01CA252211
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Frameworks to Guide Faculty Development for Health Professions Education: A Scoping Review
Journal of Continuing Education in the Health Professions
2021 - Healthcare use and costs in adult cancer patients with anxiety and depression
Depression and Anxiety
2020
Similar KOLs
Other experts from the same institution or the same specialty.
Bruce A. Perkins
Sinai Health System
Nancy Glick, MD
Sinai Health System
Adelina Hung, MD
Sinai Health System
Gautam Valecha, MBBS
Sinai Health System
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”